COGT - NASDAQ

Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGTยทNASDAQ

$32.26

+0.19%
HealthcareBiotechnology

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$5.51B
EPS-2.5500
P/E Ratio-12.65
Earnings Date08/04/2026
Cogent Biosciences, Inc.

Cogent Biosciences, Inc. Fair Value Envelope

COGT ยท NASDAQ

Our analysis suggests that COGT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $32.26, this represents a potential HIDDEN relative to our calculated worth for Cogent Biosciences, Inc..

HIDDEN
Intrinsic Value
Current Price: $32.26

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$527.3M
+ Cash & Equivalents$312.0M
Firm Value-$215.3M
- Debt$253.2M
Equity Value-$468.5M
/ Shares Outstanding142,452,618B
DCF Value-$3
OVERVALUED BY 110%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$191.3M
-$138.4M
-$100.1M
-$72.4M
-$52.4M
-$37.9M
-$27.4M
-$19.8M
-$14.3M
-$10.4M
Maintenance CapEx
-$224.8K
-$162.6K
-$117.7K
-$85.1K
-$61.6K
-$44.5K
-$32.2K
-$23.3K
-$16.9K
-$12.2K
Owner Earnings
-$191.5M
-$138.5M
-$100.2M
-$72.5M
-$52.4M
-$37.9M
-$27.4M
-$19.9M
-$14.4M
-$10.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$177.3M
-$118.8M
-$79.6M
-$53.3M
-$35.7M
-$23.9M
-$16.0M
-$10.7M
-$7.2M
-$4.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your COGT research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.